Tiziana Life Sciences plc

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Pays $35m Up Front To Access Lyci

In what it describes as a “substantial boost” for the UK’s vaccine manufacturing capacity, the government has announced an additional £100m (US$130m) in funding for a state-of-the-art production cente

The US may be in Thanksgiving mode, but companies in other parts of the world continue to come forward with venture capital investment news, including China's Alphamab Oncology with a $100m Series A

Investors can't seem to get enough of biopharmaceutical companies developing drugs for non-alcoholic steatohepatitis (NASH), an indication with potentially millions of patients, no approved therapies